Predictive value of metabolic activity detected by pre-operative 18F FDG PET/CT in ampullary adenocarcinoma

In ampullary adenocarcinoma cases, the clinical effects of F-18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) have not yet been well-studied, unlike other prognostic factors that have been reported till date. This study aimed to investigate the clinical impact of maximum standardized uptake value (SUVmax) in predicting the prognosis of ampullary adenocarcinoma. Thirty-eight patients who underwent pre-operative F-18-FDG PET/CT and curative-intent resection of ampullary adenocarcinoma at Pusan National University Hospital (Pusan, South Korea) between 2008 and 2017 were retrospectively analyzed in this study. We evaluated the clinicopathologic outcomes according to the SUVmax using univariate and multivariate Cox proportional hazard regression analyses and receiver operating characteristic analysis to arrive at a cutoff value. Lymph node metastasis was detected in 9 patients, and 15 patients experienced a recurrence during the follow-up period. Among 38 patients, 33 showed an increased FDG uptake by the main tumor. SUVmax of 4.55 was selected as a significant independent predictive factor for patient survival along with poor tumor differentiation and high neutrophil-to-lymphocyte ratio in multivariate analysis (P = .016, hazard ratio = 5.040). Patients with SUVmax under 4.55 exhibited significantly longer overall survival than the rest (<4.55 vs >= 4.55), and the 5-year overall survival was 82.8% versus 57.4% (P = .049). SUVmax of 4.55 on F-18-FDG PET/CT could be a predictive factor for tumor biology and long-term survival in patients with ampullary adenocarcinoma. Nevertheless, considering the cost aspect and its limited prognostic effect, this study seems to require more patient and multicenter studies.

Automated summary

The study retrospectively analyzed 38 patients with ampullary adenocarcinoma and found that an SUVmax of 4.55 on F-18-FDG PET/CT is an independent predictive factor for long-term survival, with patients below 4.55 exhibiting longer overall survival.